Baxdrostat is the first aldosterone synthase inhibitor approved in the US for the treatment of uncontrolled hypertension.
Answers are grounded in this paper and cite their sources.
First approved aldosterone synthase inhibitor for resistant hypertension; extends options while leaving comparative outcomes open.
The FDA has approved baxdrostat (Baxfendy – AstraZeneca), an oral aldosterone synthase inhibitor, for add-on treatment of hypertension in adults whose blood pressure is not adequately controlled on other drugs. Baxdrostat is the first aldosterone synthase inhibitor to become available in the US.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: